Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IL-23 promotes tumour incidence and growth


Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century1. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation2. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer3. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle4,5,6,7. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Overexpression of IL-23 but not of IL-12 in human cancer.
Figure 2: Tumour resistance with reduced inflammation in IL-23-deficient animals.
Figure 3: IL-12 stimulates, but IL-23 decreases, immune surveillance by CD8 T cells.
Figure 4: Functional ablation of IL-23p19 signalling restricts tumour growth.


  1. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001)

    Article  CAS  Google Scholar 

  2. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002)

    Article  ADS  CAS  Google Scholar 

  3. Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137–148 (2004)

    Article  CAS  Google Scholar 

  4. Yee, C. & Greenberg, P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nature Rev. Cancer 2, 409–419 (2002)

    Article  CAS  Google Scholar 

  5. Blattman, J. N. & Greenberg, P. D. Cancer immunotherapy: a treatment for the masses. Science 305, 200–205 (2004)

    Article  ADS  CAS  Google Scholar 

  6. Marincola, F. M., Wang, E., Herlyn, M., Seliger, B. & Ferrone, S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 24, 335–342 (2003)

    Article  CAS  Google Scholar 

  7. Ganss, R., Arnold, B. & Hammerling, G. J. Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur. J. Immunol. 34, 2635–2641 (2004)

    Article  CAS  Google Scholar 

  8. Langrish, C. L. et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202, 96–105 (2004)

    Article  CAS  Google Scholar 

  9. Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715–725 (2000)

    Article  CAS  Google Scholar 

  10. Parham, C. et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699–5708 (2002)

    Article  CAS  Google Scholar 

  11. Harrington, L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6, 1123–1132 (2005)

    Article  CAS  Google Scholar 

  12. Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910–1914 (2003)

    Article  CAS  Google Scholar 

  13. Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744–748 (2003)

    Article  ADS  CAS  Google Scholar 

  14. Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005)

    Article  CAS  Google Scholar 

  15. Numasaki, M. et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620–2627 (2003)

    Article  CAS  Google Scholar 

  16. Gupta, J. W., Kubin, M., Hartman, L., Cassatella, M. & Trinchieri, G. Induction of expression of genes encoding components of the respiratory burst oxidase during differentiation of human myeloid cell lines induced by tumor necrosis factor and gamma-interferon. Cancer Res. 52, 2530–2537 (1992)

    CAS  PubMed  Google Scholar 

  17. Girardi, M. et al. The distinct contributions of murine T cell receptor (TCR)γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer. J. Exp. Med. 198, 747–755 (2003)

    Article  CAS  Google Scholar 

  18. Stark, M. A. et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22, 285–294 (2005)

    Article  CAS  Google Scholar 

  19. Mueller, M. M. et al. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am. J. Pathol. 155, 1557–1567 (1999)

    Article  CAS  Google Scholar 

  20. Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490 (2000)

    Article  CAS  Google Scholar 

  21. Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000)

    Article  CAS  Google Scholar 

  22. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Rev. Immunol. 3, 133–146 (2003)

    Article  CAS  Google Scholar 

  23. Lo, C. H. et al. Antitumor and antimetastatic activity of IL-23. J. Immunol. 171, 600–607 (2003)

    Article  CAS  Google Scholar 

  24. Tiano, H. F. et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62, 3395–3401 (2002)

    CAS  PubMed  Google Scholar 

  25. Lieberman, L. A. et al. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J. Immunol. 173, 1887–1893 (2004)

    Article  CAS  Google Scholar 

  26. Khader, S. A. et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-γ responses if IL-12p70 is available. J. Immunol. 175, 788–795 (2005)

    Article  CAS  Google Scholar 

  27. Lee, E. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125–130 (2004)

    Article  CAS  Google Scholar 

  28. Nagase, H., Mao, J. H. & Balmain, A. A subset of skin tumor modifier loci determines survival time of tumor-bearing mice. Proc. Natl Acad. Sci. USA 96, 15032–15037 (1999)

    Article  ADS  CAS  Google Scholar 

  29. Fusenig, N. E., Am, S. M., Boukamp, P. & Worst, P. K. Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo. Bull. Cancer 65, 271–279 (1978)

    CAS  PubMed  Google Scholar 

  30. Wysocka, M. et al. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25, 672–676 (1995)

    Article  CAS  Google Scholar 

Download references


We thank C. Strader for her comments on the manuscript. Author Contributions J.L.L. and X.Z. contributed equally to this work.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Martin Oft.

Ethics declarations

Competing interests

Reprints and permissions information is available at The authors declare no competing financial interests.

Supplementary information

Supplementary Notes

This file contains Supplementary Figures 1–8 and the Supplementary Methods. (PDF 1152 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Langowski, J., Zhang, X., Wu, L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461–465 (2006).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing